Advanced search
Publication Cover
OncoImmunology Volume 4, 2015 - Issue 11
Submit an article Journal homepage
2,209
Views
26
CrossRef citations to date
0
Altmetric
Original Research

In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity

Michaela Prchal-MurphyInstitute of Animal Breeding and Genetics; University of Veterinary Medicine; Vienna, Austria;Institute of Pharmacology and Toxicology; University of Veterinary Medicine; Vienna, Austria
,
Agnieszka Witalisz-SieprackaInstitute of Animal Breeding and Genetics; University of Veterinary Medicine; Vienna, Austria
,
Karoline T BednarikInstitute of Animal Breeding and Genetics; University of Veterinary Medicine; Vienna, Austria
,
Eva Maria PutzInstitute of Pharmacology and Toxicology; University of Veterinary Medicine; Vienna, Austria
,
Dagmar GotthardtInstitute of Pharmacology and Toxicology; University of Veterinary Medicine; Vienna, Austria
,
Katrin MeisslInstitute of Animal Breeding and Genetics; University of Veterinary Medicine; Vienna, Austria
,
Veronika SexlInstitute of Pharmacology and Toxicology; University of Veterinary Medicine; Vienna, Austria
,
Mathias MüllerInstitute of Animal Breeding and Genetics; University of Veterinary Medicine; Vienna, Austria;Biomodels Austria; University of Veterinary Medicine; Vienna, Austria
&
Birgit StroblInstitute of Animal Breeding and Genetics; University of Veterinary Medicine; Vienna, AustriaCorrespondence[email protected]
 show all
Article: e1047579 | Received 05 Dec 2014, Accepted 29 Apr 2015, Published online: 14 Sep 2015

Citations (26)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Stefan Moritsch, Bernadette Mödl, Irene Scharf, Lukas Janker, Daniela Zwolanek, Gerald Timelthaler, Emilio Casanova, Maria Sibilia, Thomas Mohr, Lukas Kenner, Dietmar Herndler-Brandstetter, Christopher Gerner, Mathias Müller, Birgit Strobl & Robert Eferl. (2022) Tyk2 is a tumor suppressor in colorectal cancer. OncoImmunology 11:1.
Read now
Xingrui He, Xiabin Chen, Hancheng Zhang, Tian Xie & Xiang-Yang Ye. (2019) Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018). Expert Opinion on Therapeutic Patents 29:2, pages 137-149.
Read now

Articles from other publishers (24)

Ole Haagen Nielsen, Theresa Louise Boye, Deepavali Chakravarti & John Gubatan. (2022) Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. Trends in Pharmacological Sciences 43:5, pages 424-436.
Crossref
Hong-Tai Tzeng, I-Tsu Chyuan & Jenn-Haung Lai. (2021) Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential. Biochemical Pharmacology 193, pages 114760.
Crossref
Dana C. Borcherding, Kevin He, Neha V. Amin & Angela C. Hirbe. (2021) TYK2 in Cancer Metastases: Genomic and Proteomic Discovery. Cancers 13:16, pages 4171.
Crossref
Dominika Hromadová, Dirk Elewaut, Robert D. Inman, Birgit Strobl & Eric Gracey. (2021) From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases. Frontiers in Genetics 12.
Crossref
Klara Klein, Dagmar Stoiber, Veronika Sexl & Agnieszka Witalisz-Siepracka. (2021) Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?. Cancers 13:11, pages 2611.
Crossref
Leonie C S De Vries, Mohammed Ghiboub, Patricia H P van Hamersveld, Olaf Welting, Caroline Verseijden, Matthew J Bell, Inmaculada Rioja, Rabinder K Prinjha, Pim J Koelink, Birgit Strobl, Mathias Müller, Geert R D’Haens, Manon E Wildenberg & Wouter J De Jonge. (2021) Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis. Journal of Crohn's and Colitis 15:4, pages 617-630.
Crossref
Andrea Poelzl, Caroline Lassnig, Simone Tangermann, Dominika Hromadová, Ursula Reichart, Riem Gawish, Kristina Mueller, Richard Moriggl, Andreas Linkermann, Martin Glösmann, Lukas Kenner, Mathias Mueller & Birgit Strobl. (2020) TYK2 licenses non-canonical inflammasome activation during endotoxemia. Cell Death & Differentiation 28:2, pages 748-763.
Crossref
Edgar Turrubiartes-Martínez, Irene Bodega-Mayor, Pablo Delgado-Wicke, Francisca Molina-Jiménez, Diana Casique-Aguirre, Martín González-Andrade, Inmaculada Rapado, Mireia Camós, Cristina Díaz-de-Heredia, Eva Barragán, Manuel Ramírez-Orellana, Beatriz Aguado, Ángela Figuera, Joaquín Martínez-López & Elena Fernández-Ruiz. (2020) TYK2 Variants in B-Acute Lymphoblastic Leukaemia. Genes 11:12, pages 1434.
Crossref
Katrin Meissl, Natalija Simonović, Lena Amenitsch, Agnieszka Witalisz-Siepracka, Klara Klein, Caroline Lassnig, Ana Puga, Claus Vogl, Andrea Poelzl, Markus Bosmann, Alexander Dohnal, Veronika Sexl, Mathias Müller & Birgit Strobl. (2020) STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity. Frontiers in Immunology 11.
Crossref
Feng Yu, Yuanyuan Lin, Xinping Xu, Weipeng Liu, Dan Tang, Xiaochen Zhou, Gongxian Wang, Yi Zheng & An Xie. (2020) Knockdown of GSG2 inhibits prostate cancer progression in�vitro and in�vivo. International Journal of Oncology.
Crossref
Anzhelika Karjalainen, Stephen Shoebridge, Milica Krunic, Natalija Simonović, Graham Tebb, Sabine Macho-Maschler, Birgit Strobl & Mathias Müller. (2020) TYK2 in Tumor Immunosurveillance. Cancers 12:1, pages 150.
Crossref
Dagmar Gotthardt, Jana Trifinopoulos, Veronika Sexl & Eva Maria Putz. (2019) JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation. Frontiers in Immunology 10.
Crossref
Alexander Vargas-Hernández & Lisa R. Forbes. (2019) JAK/STAT proteins and their biological impact on NK cell development and function. Molecular Immunology 115, pages 21-30.
Crossref
Tomoki Motegi, Yuta Kochi, Koichi Matsuda, Michiaki Kubo, Kazuhiko Yamamoto & Yukihide Momozawa. (2019) Identification of rare coding variants in TYK2 protective for rheumatoid arthritis in the Japanese population and their effects on cytokine signalling . Annals of the Rheumatic Diseases 78:8, pages 1062-1069.
Crossref
Natalija Simonović, Agnieszka Witalisz-Siepracka, Katrin Meissl, Caroline Lassnig, Ursula Reichart, Thomas Kolbe, Matthias Farlik, Christoph Bock, Veronika Sexl, Mathias Müller & Birgit Strobl. (2019) NK Cells Require Cell-Extrinsic and -Intrinsic TYK2 for Full Functionality in Tumor Surveillance and Antibacterial Immunity. The Journal of Immunology 202:6, pages 1724-1734.
Crossref
Subburaj Ilangumaran, Bryan R.G. Williams & Dhan V. Kalvakolanu. (2018) Meeting summary: 2nd Aegean Conference on Cytokine Signaling in Cancer. Cytokine 108, pages 225-231.
Crossref
Michiko Nemoto, Hiroyoshi Hattori, Naoko Maeda, Nobuhiro Akita, Hideki Muramatsu, Suzuko Moritani, Tomonori Kawasaki, Masami Maejima, Hirotaka Ode, Atsuko Hachiya, Wataru Sugiura, Yoshiyuki Yokomaku, Keizo Horibe & Yasumasa Iwatani. (2018) Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia. Scientific Reports 8:1.
Crossref
Andrea Majoros, Ekaterini Platanitis, Elisabeth Kernbauer-Hölzl, Felix Rosebrock, Mathias Müller & Thomas Decker. (2017) Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses. Frontiers in Immunology 8.
Crossref
Dagmar Gotthardt & Veronika Sexl. (2017) STATs in NK-Cells: The Good, the Bad, and the Ugly. Frontiers in Immunology 7.
Crossref
Katrin Meissl, Sabine Macho-Maschler, Mathias Müller & Birgit Strobl. (2017) The good and the bad faces of STAT1 in solid tumours. Cytokine 89, pages 12-20.
Crossref
Nicole R. Leitner, Agnieszka Witalisz-Siepracka, Birgit Strobl & Mathias Müller. (2017) Tyrosine kinase 2 – Surveillant of tumours and bona fide oncogene. Cytokine 89, pages 209-218.
Crossref
Sebastian Fuchs, Petra Kaiser-Labusch, Julia Bank, Sandra Ammann, Anja Kolb-Kokocinski, Christine Edelbusch, Heymut Omran & Stephan Ehl. (2016) Tyrosine kinase 2 is not limiting human antiviral type III interferon responses. European Journal of Immunology 46:11, pages 2639-2649.
Crossref
Ewa Marcinkowska & Elżbieta Gocek. 2016. Resistance to Tyrosine Kinase Inhibitors. Resistance to Tyrosine Kinase Inhibitors 1 25 .
Donal P. McLornan, Alesia A. Khan & Claire N. Harrison. (2015) Immunological Consequences of JAK Inhibition: Friend or Foe?. Current Hematologic Malignancy Reports 10:4, pages 370-379.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.